154 results on '"Wu, Qian Vicky"'
Search Results
2. Feasibility and favorable responses after investigational CAR T-cell therapy for relapsed and refractory infant ALL
3. Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy
4. GFAP and NfL increase during neurotoxicity from high baseline levels in pediatric CD19-CAR T-cell patients
5. Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy
6. Hematopoietic Cell Transplantation after CD19 Chimeric Antigen Receptor T Cell-Induced Acute Lymphoblastic Leukemia Remission Confers a Leukemia-Free Survival Advantage
7. Ibrutinib Monotherapy in Relapsed or Refractory, Transformed Diffuse Large B-cell Lymphoma
8. Post-CAR-T Checkpoint Inhibition Can Result in Durable Responses in a Minority of Patients with Multiple Myeloma (MM) or Non-Hodgkin's Lymphoma (NHL): Results of a Phase 2 Study of Nivolumab after CAR-T Failure
9. Timing of Anti-PD-L1 Antibody Initiation Affects Efficacy/Toxicity of CD19 CAR-T Cell Therapy for Large B-Cell Lymphoma
10. Data from Modified Manufacturing Process Modulates CD19CAR T-cell Engraftment Fitness and Leukemia-Free Survival in Pediatric and Young Adult Subjects
11. Supplementary Data from Modified Manufacturing Process Modulates CD19CAR T-cell Engraftment Fitness and Leukemia-Free Survival in Pediatric and Young Adult Subjects
12. Supplementary Data from A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer
13. Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy
14. Peripheral lymphocytes and lactate dehydrogenase correlate with response and survival in head and neck cancers treated with immune checkpoint inhibitors
15. Predictors of response to axicabtagene‐ciloleucel CAR T cells in aggressive B cell lymphomas: A real‐world study
16. Neutrophil to lymphocyte ratio and peripheral blood biomarkers correlate with survival outcomes but not response among head and neck and salivary cancer treated with pembrolizumab and vorinostat
17. Timing of PD-L1 Blockade with Durvalumab May Affect Outcomes of CD19 CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma
18. Impact of Hematopoietic Cell Transplantation after CAR T-Cell Therapy for B-ALL: Comparison of Statistical Models and Survival Curves By a Novel R Shiny Tool
19. Minimally Invasive Blood Sampling for BCR::ABL1 transcript Monitoring
20. 19 Peripheral lymphocytes and lactate dehydrogenase correlate with improved response and survival in head and neck cancer treated with immune checkpoint inhibitors
21. GFAP and NfL increase during neurotoxicity from high baseline levels in pediatric CD19-CAR T-cell patients
22. Predictors of cytopenias after treatment with axicabtagene ciloleucel in patients with large B-cell lymphoma
23. Modified Manufacturing Process Modulates CD19CAR T-cell Engraftment Fitness and Leukemia-Free Survival in Pediatric and Young Adult Subjects
24. Performance status ( PS ) as a predictor of poor response to immune checkpoint inhibitors ( ICI ) in recurrent/metastatic head and neck cancer ( RMHNSCC ) patients
25. Space-log: a novel approach to inferring gene-gene net-works using SPACE model with log penalty
26. Neutrophil to lymphocyte ratio and peripheral blood biomarkers correlate with survival outcomes but not response among head and neck and salivary cancer treated with pembrolizumab and vorinostat.
27. High End-of-Life Health Care Utilization in a Contemporary Cohort of Head and Neck Cancer Patients Treated with Immune Checkpoint Inhibitors
28. Rare Variant Genetic Association Study for Transplant-Associated Thrombotic Microangiopathy (TA-TMA) Via Whole Exome Sequencing
29. Access to CAR-T Cell Therapy in Underrepresented Populations: A Multicenter Cohort Study of Pediatric and Young Adult ALL Patients
30. SCRI-CAR19x22v2 T Cell Product Demonstrates Bispecific Activity in B-ALL
31. Safety and Efficacy of Fully Human BCMA CAR T Cells in Combination with a Gamma Secretase Inhibitor to Increase BCMA Surface Expression in Patients with Relapsed or Refractory Multiple Myeloma
32. Development and Validation of the Individual Burden of Illness Index for Major Depressive Disorder (IBI-D)
33. A Phase 2 Trial of SCRI-CAR19 Demonstrates Favorable Leukemia-Free Survival (LFS), with a Pilot Study of CD19-Expressing T-Cell Antigen Presenting Cells (CD19t T-APCs) Demonstrating Safety and Tolerability
34. Inaccessible LCG Promoters Act as Safeguards to Restrict T Cell Development to Appropriate Notch Signaling Environments
35. Abstract OT-13-07: Phase I study of adoptive immunotherapy for advanced MUC1* positive breast cancer with autologous T cells engineered to express a chimeric antigen receptor, huMNC2-CAR44 specific for a cleaved form of MUC1 (MUC1*)
36. Gender Differences in Faculty Rank and Subspecialty Choice among Academic Medical Oncologists
37. Patient-Reported Outcomes at Time of CAR-T Cell Therapy
38. Predictors of Cytopenia after Treatment with Axicabtagene Ciloleucel in Patients with Large Cell Lymphoma
39. Pembrolizumab with R-CHOP in Previously Untreated Diffuse Large B-Cell Lymphoma: Long Term Follow up and Analysis of the Mechanism of Pdl-1 Tumor Expression
40. Space-log: a novel approach to inferring gene-gene net-works using SPACE model with log penalty
41. Abstract P1-01-07: The role of18F-Fluoroestradiol (FES) and18F-Fluorodeoxyglucose (FDG) PET imaging in identification of bone metastases in metastatic breast cancer
42. A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer
43. Novel CD19t T-Antigen Presenting Cells Expand CD19 CAR T Cells In Vivo
44. Soluble C5b-9 As a Prognostic Biomarker for Thrombotic Microangiopathy at the Onset of Graft-Versus-Host Disease
45. Phase II Window Study of Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases
46. D-Dimer As a Prognostic Biomarker for Venous Thromboembolism after Hematopoietic Cell Transplantation
47. Clinical Experience of CAR T Cell Immunotherapy for Relapsed and Refractory Infant ALL Demonstrates Feasibility and Favorable Responses
48. Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen Receptor (CAR)-T Cell Therapy
49. Severe Cytokine Release Syndrome Is Associated with Impaired Hematopoietic Recovery after CD19-Targeted CAR-T Cell Therapy
50. Ibrutinib in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma: Final Results from a Prospective Phase II Study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.